Has Jecinter Otieno received payments from drug or device companies?

Yes. Drug and device makers reported $3,795 in general payments to Jecinter Otieno across 133 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jecinter Otieno did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jecinter Otieno come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jecinter Otieno

Psychiatric/Mental Health · Binghamton, NYNPI 1619578366

Payments from drug & device makers

$3,795in general payments, 2019–2025

Across 133 payments — averaging $28.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$955
Johnson & Johnson$943
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$706
Teva Pharmaceuticals USA, Inc.$357
Sunovion Pharmaceuticals Inc.$194
Alkermes, Inc.$171
plus $468 from 9 others

What the payments were for

Food & beverage$3,65196%
Education$1434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	39	$955
Johnson & Johnson	18	$943
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	23	$706
Teva Pharmaceuticals USA, Inc.	10	$357
Sunovion Pharmaceuticals Inc.	11	$194
Alkermes, Inc.	6	$171
Otsuka America Pharmaceutical, Inc.	7	$138
Takeda Pharmaceuticals U.S.A., Inc.	5	$84
Vanda Pharmaceuticals Inc.	3	$57
Bausch Health US, LLC	3	$53
Neurocrine Biosciences, Inc.	2	$39
Axsome Therapeutics, Inc.	2	$34
Lundbeck LLC	2	$26
Indivior Inc.	1	$20
Ironshore Pharmaceuticals Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,795 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VraylarCariprazine Hcl	147	$221,747
Invega SustennaPaliperidone Palmitate	59	$208,465
Invega TrinzaPaliperidone Palmitate	19	$184,422
RexultiBrexpiprazole	38	$58,123
Chlorpromazine Hcl	117	$57,769
Aripiprazole	726	$56,585
CaplytaLumateperone Tosylate	30	$49,917
TrintellixVortioxetine Hydrobromide	90	$48,593
Quetiapine Fumarate	488	$38,813
Divalproex Sodium	374	$30,025
Lurasidone Hcl	161	$29,683
Olanzapine	535	$26,461
Fluvoxamine Maleate	345	$23,222
Divalproex Sodium ErDivalproex Sodium	194	$20,938
Risperidone	687	$17,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Concerta, Risperdal	$943	$408,472112 claims
AbbVieVraylar, Saphris	$955	$232,489166 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse	$84	$59,625117 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$138	$58,12338 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$706	$49,91730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Binghamton

Elijah StevensBinghamton$131K
Glenn HannDansville$1.3M
Tammy RussoNiskayuna$568K
Carrie EdickSchenectady$484K
Eric SpronzCentereach$448K
Terry Jo Brooks-DevlinTonawanda$176K
Kevin SiewersStaten Island$155K
Daniel BreeyearNiskayuna$149K
Mary OlsonNew York$142K
Kayanna JonasFar Rockaway$93K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →